Ramucirumab plus FOLFIRI or irinotecan as second-line treatment for patients with gastroesophageal adenocarcinoma: a review and meta-analysis of an emerging option

By sjmartinez • September 1, 2024

Park H, Klempner SJ, Chao J, Wainberg ZA, Lukanowski M, Chenji S, Bourke S, Chatterjee A, Lorenzen S. Ramucirumab plus FOLFIRI or irinotecan as second-line treatment for patients with gastroesophageal adenocarcinoma: a review and meta-analysis of an emerging option. Front Oncol. 2024 Aug 13;14:1419338. doi: 10.3389/fonc.2024.1419338. PMID: 39206150; PMCID: PMC11353394.

Tags: FOLFIRI, gastroesophageal adenocarcinoma, Hematology/Oncology, irinotecan, Publications, ramucirumab, second-line

daNIS-2: a phase III, randomized, double-blind study of the anti-TGF-β monoclonal antibody NIS793 or placebo in combination with nab-paclitaxel/gemcitabine as first-line treatment in patients with metastatic pancreatic ductal adenocarcinoma

Paulson S, Ikeda M, Shen L, Stein A, Macarulla T, Milella M, Golan T, Wainberg Z, Taieb J, Wang L, Polydoros F, Abecunas C, López[...]

Anti-trophoblast Cell-Surface Antigen 2 (TROP2)-Based Therapy for Concurrent Breast and Thyroid Malignancies

Berkowitz MJ, Arzoo KK. Anti-trophoblast Cell-Surface Antigen 2 (TROP2)-Based Therapy for Concurrent Breast and Thyroid Malignancies. Cureus. 2026 Oct 6;18(10):e117545. doi: 10.7759/cureus.117545. PMID: 42992212; PMCID:[...]

PADL1NK-005 study design: a phase III trial of fetrastobart vedotin (Fetra-V) vs docetaxel in patients with previously treated tumor PD-L1-positive NSCLC

Altan M, Navani V, Kim HR, Sun L, Paz-Ares L, Chmielewska I, Lin CC, Cuppens K, Mountzios I, Peled N, Cappuzzo F, Wang B, Zhou[...]